← Leaderboards
Peng Huang
University Of Texas Md Anderson Can Ctr
$9,110,063
Attributed
$9,110,063
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $872.3K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$9,110,063 · 6
By mechanism
R01$8,472,039 · 4
R29$331,424 · 1
R21$306,600 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- William K Plunkett$8,981,153
- Catherine A. O'Brian$764,320
Others in their field
Top investigators on “Oxidative Stress”
- Leonardo Trasande · New York University School Of Medicine$57,471,048
- Rosalind J Wright · Icahn School Of Medicine At Mount Sinai$36,739,005
- Claire Gmachl · Princeton University$34,397,540
- Akram N Alshawabkeh · Northeastern University$31,872,089
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$31,629,832
- Robert O Wright · Brigham And Women'S Hospital$30,479,869
Research focus
Oxidative StressApoptosisCellsReactive Oxygen SpeciesBiochemicalGenerationsMediatingInsightMitochondriaNovel TherapeuticsBaseKillingsPharmaceutical PreparationsIn VivoOxidation-ReductionPlayDrug ResistanceCell DeathCancer CellLeukemiaStressLeadDesignNormal Cell
Grant awards (38)
Novel Strategies to Target Leukemia-Stromal Interactions$366,000
R01 · FY2017 · CA · contact PI
Novel Strategies to Target Leukemia-Stromal Interactions$366,000
R01 · FY2016 · CA · contact PI
ROS, Redox Regulation and Novel Targets for Cancer Therapy$233,579
R01 · FY2016 · CA · contact PI
Novel Strategies to Target Leukemia-Stromal Interactions$366,000
R01 · FY2015 · CA · contact PI
ROS, Redox Regulation and Novel Targets for Cancer Therapy$233,579
R01 · FY2015 · CA · contact PI
ROS, Redox Regulation and Novel Targets for Cancer Therapy$226,572
R01 · FY2014 · CA · contact PI
ROS, Redox Regulation and Novel Targets for Cancer Therapy$219,564
R01 · FY2013 · CA · contact PI
Novel Roles of p53 & ROS in Therapy of Refractory CLL$290,708
R01 · FY2012 · CA · contact PI
ROS, Redox Regulation and Novel Targets for Cancer Therapy$233,579
R01 · FY2012 · CA · contact PI
Novel Roles of p53 & ROS in Therapy of Refractory CLL$290,708
R01 · FY2011 · CA · contact PI
Novel Roles of p53 & ROS in Therapy of Refractory CLL$299,699
R01 · FY2010 · CA · contact PI
Superoxide, ROS, and novel targets for cancer therapy$227,666
R01 · FY2010 · CA · contact PI
Novel Roles of p53 & ROS in Therapy of Refractory CLL$299,699
R01 · FY2009 · CA · contact PI
Superoxide, ROS, and novel targets for cancer therapy$227,666
R01 · FY2009 · CA · contact PI
Mitochondrial defects and Cancer Therapeutics$293,511
R01 · FY2008 · CA · contact PI
Superoxide, ROS, and novel targets for cancer therapy$227,666
R01 · FY2008 · CA · contact PI
Mitochondrial defects and Cancer Therapeutics$293,511
R01 · FY2007 · CA · contact PI
p53 in Cellular Response to ROS-Mediated DNA Damage$286,708
R01 · FY2007 · CA · contact PI
Superoxide, ROS, and novel targets for cancer therapy$227,666
R01 · FY2007 · CA · contact PI
Mitochondrial defects and Cancer Therapeutics$53,467
R01 · FY2007 · CA · contact PI
Mitochondrial defects and Cancer Therapeutics$302,276
R01 · FY2006 · CA · contact PI
p53 in Cellular Response to ROS-Mediated DNA Damage$295,271
R01 · FY2006 · CA · contact PI
Superoxide, ROS, and novel targets for cancer therapy$234,465
R01 · FY2006 · CA · contact PI
Mitochondrial defects and Cancer Therapeutics$40,245
R01 · FY2006 · CA · contact PI
Mitochondrial defects and Cancer Therapeutics$309,550
R01 · FY2005 · CA
p53 in Cellular Response to ROS-Mediated DNA Damage$302,378
R01 · FY2005 · CA
Antitumor Activity &Mechanism of OSW-1 in Pancreatic Ca$146,925
R21 · FY2005 · CA
Mitochondrial defects and Cancer Therapeutics$309,550
R01 · FY2004 · CA
p53 in Cellular Response to ROS-Mediated DNA Damage$302,378
R01 · FY2004 · CA
SUPEROXIDE DISMUTASE--A NOVEL TARGET FOR CANCER THERAPY$202,500
R01 · FY2004 · CA
Antitumor Activity &Mechanism of OSW-1 in Pancreatic Ca$159,675
R21 · FY2004 · CA
p53 in Cellular Response to ROS-Mediated DNA Damage$302,378
R01 · FY2003 · CA
SUPEROXIDE DISMUTASE--A NOVEL TARGET FOR CANCER THERAPY$202,500
R01 · FY2003 · CA
SUPEROXIDE DISMUTASE--A NOVEL TARGET FOR CANCER THERAPY$202,500
R01 · FY2002 · CA
P53 AND REPAIR OF DNA DAMAGE BY ANTICANCER DRUGS$115,906
R29 · FY2002 · CA
SUPEROXIDE DISMUTASE--A NOVEL TARGET FOR CANCER THERAPY$202,500
R01 · FY2001 · CA
P53 AND REPAIR OF DNA DAMAGE BY ANTICANCER DRUGS$110,387
R29 · FY2001 · CA
P53 AND REPAIR OF DNA DAMAGE BY ANTICANCER DRUGS$105,131
R29 · FY2000 · CA